Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
ID: 351499Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $300K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351499

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-017.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for the Early-Stage Development of Informatics Technologies for Cancer Research and Management, aimed at advancing innovative informatics tools that enhance data acquisition, management, and analysis in cancer research. The initiative focuses on developing tools that engage users and address various aspects of cancer research, including biology, treatment, early detection, and health disparities, with an emphasis on early-stage development. Approximately $2.25 million is available for 5-6 awards, with individual budgets capped at $300,000 per year for a maximum of three years. Applications are due by November 15, 2024, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-017.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-24-017-Full-Announcement.html
    RFA-CA-24-017.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Notice of Funding Opportunity (NOFO) seeking applications for the Early-Stage Development of Informatics Technologies for Cancer Research and Management. This funding aims to support the development of innovative informatics tools that enhance data acquisition, management, and analysis across various aspects of cancer research, including biology, treatment, early detection, and health disparities. The program focuses on early-stage tool development, emphasizing user engagement and feedback to ensure relevance and effectiveness in the cancer research community. Funding of approximately $2.25 million is available for 5-6 awards, with budgets capped at $300,000 per year over a maximum of three years. Eligible applicants include higher education institutions, nonprofits, and various governmental bodies. Applications are due by November 15, 2024, with a range of specific requirements outlined for submission and review processes to ensure adherence to NIH standards. Overall, this initiative supports the advancement of informatics technologies crucial for enhancing cancer research outcomes and collaboration among various stakeholders.
    Similar Opportunities
    Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on the development and validation of innovative technologies designed to enhance cancer research methodologies, particularly in areas such as diagnostics, treatment, and addressing health disparities. The funding program is part of the National Cancer Institute's (NCI) Innovative Molecular Analysis Technologies (IMAT) Program, with a total estimated funding of $4.3 million available for approximately 10 awards, each capped at $300,000 per year for projects lasting up to three years. Interested applicants must submit their proposals by October 3, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This grant aims to support exploratory research projects that focus on the development and validation of innovative technologies to enhance the quality and handling of cancer-relevant biospecimens, addressing significant gaps in cancer research methodologies. The initiative is part of the National Cancer Institute's (NCI) broader Innovative Molecular Analysis Technologies (IMAT) Program, which seeks to improve cancer biology research, early detection, clinical diagnosis, and treatment, while also tackling health disparities. Eligible applicants can receive up to $300,000 per year for a maximum of three years, with a submission deadline of October 3, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-004.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the opportunity titled "Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding initiative aims to support exploratory research projects focused on the early-stage development of innovative technologies that enhance the quality, handling, and preservation of cancer-related biospecimens, addressing issues such as pre-analytical degradation. The initiative is part of the broader Innovative Molecular Analysis Technologies (IMAT) Program and seeks to advance cancer research, early detection, and treatment while addressing health disparities. Eligible applicants include a diverse range of institutions and organizations, with a maximum funding amount of $150,000 per year for up to three years. The application deadline is October 3, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NCI Small Grants Program for Cancer Research (R03), aimed at supporting short-term cancer research projects that require limited resources. This funding opportunity encourages diverse research efforts, including pilot studies, secondary data analyses, and the development of research methodologies, with a maximum budget of $50,000 per year for projects lasting up to two years. The program is designed to address significant knowledge gaps in cancer research and is open to a wide range of applicants, including public, private, and foreign entities. Interested parties should note that the application period opens on January 24, 2025, with a submission deadline of February 24, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem," aimed at supporting research projects that enhance cancer communication strategies. The initiative focuses on three key areas: the application of new cancer communication surveillance methods, the development of rapid pilot interventions, and the creation of multilevel communication models that emphasize bidirectional influences in cancer prevention and control. This funding, available through R21 exploratory/developmental grants, provides up to $275,000 for a maximum of two years, with applications due starting January 16, 2025. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), is offering a funding opportunity titled "Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis" under the R01 Research Project Grant program. This initiative aims to support research projects that implement early phase clinical trials (Phases 0, I, and II) focused on cancer-targeted diagnostic and therapeutic interventions, aligning with the NCI's mission to advance cancer research. Eligible applicants include a diverse range of organizations such as colleges, nonprofits, and governmental entities, with a maximum project budget of $499,999 in direct costs per year and an award period not exceeding five years. Interested parties should note that applications are due by January 7, 2027, and can seek further information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-081.html.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)." This initiative encourages applications that propose innovative secondary data analyses and integration of existing datasets to address significant scientific questions related to cancer risk, prevention, and treatment outcomes. The program aims to leverage diverse data sources, including clinical, environmental, and genomic datasets, to enhance understanding of cancer and improve public health strategies. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofit organizations, and tribal governments, with a maximum funding amount of $200,000 and a project duration of up to two years. Interested parties can find more information and application details at the NIH grants website, with the submission deadline set for September 7, 2026.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.